June 30, 2023 02:28 PM EDTUpdated July 3, 11:28 AM
China
Coronavirus
Law

CSPC to launch Paxlovid ver­sion in Chi­na; SEC charges ex-Pfiz­er em­ploy­ee with in­sid­er trad­ing

Tyler Patchen

News Reporter

Pfiz­er inked a deal with a Chi­nese phar­ma to launch a form of its Covid-19 an­tivi­ral Paxlovid in Chi­na.

The com­pa­ny is work­ing with CSPC Phar­ma­ceu­ti­cal Group, which is based in Shi­ji­azhuang, Chi­na, to pro­duce and launch a lo­cal brand of the an­tivi­ral, ac­cord­ing to a news re­lease. Bloomberg re­port­ed that Pfiz­er al­so has agree­ments with Mehe­co to sell the drug in Chi­na and Zhe­jiang Hua­hai Phar­ma­ceu­ti­cal to make and dis­trib­ute it.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Fed­er­al judge throws out two drug­mak­er IRA law­suits in win for gov­ern­ment

FDA fi­nal­izes long-await­ed rule to bring lab tests un­der its purview

WuXi wants to re­gain client con­fi­dence amid claims of IP trans­fer to Chi­nese au­thor­i­ties 

Mer­ck touts up­dat­ed 21-va­lent pneu­mo­coc­cal da­ta weeks ahead of FDA de­ci­sion: Cor­rect­ed

Ono Phar­ma­ceu­ti­cal ac­quires De­ci­phera for $2.4B af­ter biotech's Phase 3 win

sponsored

A New Pre­ci­sion Ap­proach for Non-Small Cell Lung Can­cer with EGFR Ex­on 20 In­ser­tion Mu­ta­tions

A service from the Financial Times